Identification of New Prognostic Markers for Breast Cancer.
PROBREAST
Identification de Nouveaux Marqueurs Pronostiques Des Cancers du Sein
2 other identifiers
observational
1,500
1 country
1
Brief Summary
Candidate markers have been identified thanks to an original approach developed by our research team aiming at detecting ectopic gene expression using public pan-genomic breast cancer data. The same approach had already been used and validated in lung tumors, leukemias and lymphomas. The main objective of the present research is to use tumor samples from patients in a retrospective and prospective cohort to test and validate the relevance of these prognostic markers in breast cancer.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2011
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2011
CompletedFirst Submitted
Initial submission to the registry
December 14, 2017
CompletedFirst Posted
Study publicly available on registry
February 19, 2018
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2033
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2033
February 28, 2023
February 1, 2023
23 years
December 14, 2017
February 27, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Study of ectopic gene expression to define new prognostic biomarkers in breast cancer
The overall survival and disease-free survival of patient with breast cancers will be analyzed in terms of gene expression change in order to identify new prognostic biomarkers.
12 years, with evaluation every 3 years
Secondary Outcomes (1)
Study of response to neoadjuvant treatments of breast cancer assessed from anatomopathological data.
12 years, with evaluation every 3 years
Interventions
Eligibility Criteria
Adult female patients with breast cancer
You may qualify if:
- Adult female patients with breast cancer
You may not qualify if:
- Presence of another cancer, excluding basal cell cancers or pre-neoplastic lesions of the cervix.
- Subject under guardianship or subject deprived of liberty
- Impossibility of collecting information on exposure (subjects recently arrived in France, foreign language, etc.)
- Male patients
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Anne-Cécile PHILIPPE
Grenoble, 38043, France
Related Publications (5)
Wang J, Mi JQ, Debernardi A, Vitte AL, Emadali A, Meyer JA, Charmpi K, Ycart B, Callanan MB, Carroll WL, Khochbin S, Rousseaux S. A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. Oncotarget. 2015 Jun 30;6(18):16527-42. doi: 10.18632/oncotarget.4113.
PMID: 26001296BACKGROUNDLe Bescont A, Vitte AL, Debernardi A, Curtet S, Buchou T, Vayr J, de Reynies A, Ito A, Guardiola P, Brambilla C, Yoshida M, Brambilla E, Rousseaux S, Khochbin S. Receptor-Independent Ectopic Activity of Prolactin Predicts Aggressive Lung Tumors and Indicates HDACi-Based Therapeutic Strategies. Antioxid Redox Signal. 2015 Jul 1;23(1):1-14. doi: 10.1089/ars.2013.5581. Epub 2014 Mar 6.
PMID: 24512221BACKGROUNDEmadali A, Rousseaux S, Bruder-Costa J, Rome C, Duley S, Hamaidia S, Betton P, Debernardi A, Leroux D, Bernay B, Kieffer-Jaquinod S, Combes F, Ferri E, McKenna CE, Petosa C, Bruley C, Garin J, Ferro M, Gressin R, Callanan MB, Khochbin S. Identification of a novel BET bromodomain inhibitor-sensitive, gene regulatory circuit that controls Rituximab response and tumour growth in aggressive lymphoid cancers. EMBO Mol Med. 2013 Aug;5(8):1180-95. doi: 10.1002/emmm.201202034. Epub 2013 Jul 4.
PMID: 23828858BACKGROUNDRousseaux S, Debernardi A, Jacquiau B, Vitte AL, Vesin A, Nagy-Mignotte H, Moro-Sibilot D, Brichon PY, Lantuejoul S, Hainaut P, Laffaire J, de Reynies A, Beer DG, Timsit JF, Brambilla C, Brambilla E, Khochbin S. Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013 May 22;5(186):186ra66. doi: 10.1126/scitranslmed.3005723.
PMID: 23698379BACKGROUNDReynoird N, Schwartz BE, Delvecchio M, Sadoul K, Meyers D, Mukherjee C, Caron C, Kimura H, Rousseaux S, Cole PA, Panne D, French CA, Khochbin S. Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010 Sep 1;29(17):2943-52. doi: 10.1038/emboj.2010.176. Epub 2010 Jul 30.
PMID: 20676058BACKGROUND
Biospecimen
The research uses blood samples and biopsies made at diagnosis or during surgical resection of the tumor for gene or protein expression analysis (RNA and protein extraction).
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anne-Cécile PHILIPPE, Dr
University Hospital, Grenoble
- STUDY DIRECTOR
Mireille MOUSSEAU, Pr
Grenoble Alpes University Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 14, 2017
First Posted
February 19, 2018
Study Start
January 1, 2011
Primary Completion (Estimated)
December 31, 2033
Study Completion (Estimated)
December 31, 2033
Last Updated
February 28, 2023
Record last verified: 2023-02